Norgestimate/Ethinyl Estradiol Tablets

SOL #: SPE2D2-25-D-0009Award Notice

Overview

Buyer

DEPT OF DEFENSE
Defense Logistics Agency
DLA TROOP SUPPORT
PHILADELPHIA, PA, 19111, United States

Place of Performance

Villaquilambre, Spain

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Timeline

1
Posted
Apr 7, 2025
2
Last Updated
Mar 26, 2026

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Logistics Agency (DLA) Troop Support has exercised Option Year 1 for contract SPE2D2-25-D-0009, pertaining to the supply of Norgestimate/Ethinyl Estradiol Tablets. This modification extends the period of performance from April 27, 2026, through April 26, 2027. The original award, valued at $4,229,263.40, was a Small Business Set-Aside for a requirements-type contract with an estimated 5-year duration.

Scope of Work

This contract covers the procurement of Norgestimate Ethinyl Estradiol Triphasic Low Dose Oral Tablets and related pharmaceutical products. Specific items include 3 x 28 Count (84 Tabs) formulations of 35MCG and 25MCG, as well as Ethinyl Estradiol 0.035MG/Norgestimate 0.25MG TAB, 28 (3 x 28 Count - 84 Tabs). Quantities are estimates only, as per FAR 52.216-21.

Contract & Timeline

  • Contract Number: SPE2D2-25-D-0009
  • Contract Type: Requirements-type contract (original award)
  • Original Award Value: $4,229,263.40
  • Original Estimated Duration: 5 years
  • Option Year 1 Period of Performance: April 27, 2026 – April 26, 2027
  • Set-Aside: Small Business (original award)
  • Place of Performance: Villaquilambre, Spain
  • Notice Published: March 26, 2026

Additional Notes

This notice confirms the exercise of an option year for an existing contract. The original solicitation incorporated various FAR and DFARS clauses, including FAR 52.212-1, 52.212-4, 52.212-3, and 52.212-5 by reference. The acquisition was set aside for Small Business concerns. This modification does not appear to alter submission requirements or deadlines for future actions.

Contact Information

People

Points of Contact

Kyle LewickiPRIMARY
Jason C. WraySECONDARY

Files

Files

Download

Versions

Version 2
Award Notice
Posted: Mar 26, 2026
View
Version 1Viewing
Award Notice
Posted: Apr 7, 2025
Norgestimate/Ethinyl Estradiol Tablets | GovScope